Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Mesoblast Limited (MESO) Price & Performance

Duolingo IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Mesoblast Limited — how do they compare? Duolingo Inc trades at $130.85 (market cap $5.98B), while Mesoblast Limited trades at $18.19 (market cap $2.12B). The key difference: Duolingo Inc is far larger — about 2.8× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.

DUOLMESO
Market Cap
$5.98B$2.12B
Sector
TechnologyTechnology
52-Week High
$390.84$20.96
52-Week Low
$90.03$10.96
Enterprise Value
$4.82B$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo (DUOL) trades at $132.34, up 6.08% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $127 and resistance at $135. Fundamentally, revenue grew to $1.04 billion in 2025, with net income surging to $414 million, driven by robust user engagement and AI feature expansion. Recent earnings beats and a positive analyst consensus highlight investor confidence in the company's growth trajectory.

Outlook remains positive with AI-driven user growth and profitability, but risks include rising inference costs and competitive pressures. The stock offers growth potential, yet investors should monitor margin trends and market volatility. Analyst price targets suggest moderate upside from current levels, with a consensus of $108.29.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO